Daiichi Sankyo Co Ltd D4S
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if D4S is a good fit for your portfolio.
News
-
Fusion Pharma climbs as analysts flag radiopharmaceutical company as potential merger target
-
AstraZeneca, Daiichi Sankyo's Enhertu Gets Approval in EU For Lung Cancer Treatment
-
Trending: Merck, Daiichi Sankyo Sign Development, Commercialization Deal
-
Daiichi Sankyo shares jump on multibillion-dollar drug development deal with Merck
-
Daiichi Sankyo Shares Jump on Multibillion-Dollar Drug Development Deal With Merck
-
Merck, Daiichi Sankyo Ink Commercialization Deal for Up to $22 Billion
-
AstraZeneca Says Trial Results For Breast Cancer Drug Were Highly Positive
-
AstraZeneca's Lung-Cancer Treatment Gets Recommended for Approval in the EU
Trading Information
- Previous Close Price
- JPY 32.18
- Day Range
- JPY 32.36–32.36
- 52-Week Range
- JPY 15.87–27.67
- Bid/Ask
- JPY 32.35 / JPY 32.88
- Market Cap
- JPY 62.05 Bil
- Volume/Avg
- 0 / 97
Key Statistics
- Price/Earnings (Normalized)
- 43.37
- Price/Sales
- 6.04
- Dividend Yield (Trailing)
- 0.95%
- Dividend Yield (Forward)
- 1.13%
- Total Yield
- 0.96%
Company Profile
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Growth
- Total Number of Employees
- 17,435
- Website
- https://www.daiichisankyo.com
Competitors
Valuation
|
Metric
|
D4S
|
4519
|
AZN
|
|---|---|---|---|
Price/Earnings (Normalized) | 43.37 | 25.22 | 20.85 |
Price/Book Value | 5.97 | 4.81 | 6.38 |
Price/Sales | 6.04 | 7.62 | 5.05 |
Price/Cash Flow | 36.96 | 23.75 | 23.84 |
Price/Earnings
D4S
4519
AZN
Financial Strength
|
Metric
|
D4S
|
4519
|
AZN
|
|---|---|---|---|
Quick Ratio | 2.74 | 4.21 | 0.58 |
Current Ratio | 3.49 | 5.53 | 0.82 |
Interest Coverage | 11.76 | — | 5.15 |
Quick Ratio
D4S
4519
AZN
Profitability
|
Metric
|
D4S
|
4519
|
AZN
|
|---|---|---|---|
Return on Assets (Normalized) | 7.33% | 17.64% | 59.78% |
Return on Equity (Normalized) | 13.01% | 21.05% | 157.53% |
Return on Invested Capital (Normalized) | 11.32% | 20.98% | 88.21% |
Return on Assets
D4S
4519
AZN
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Wsyxfcnqw | Rdyp | $726.1 Bil | |
JNJ
| Johnson & Johnson | Vlvdvjkt | Wsq | $367.4 Bil | |
MRK
| Merck & Co Inc | Vjlllmdfj | Zjqn | $333.6 Bil | |
ABBV
| AbbVie Inc | Bczwjyb | Tsr | $285.3 Bil | |
AZN
| AstraZeneca PLC ADR | Scjsrwyrq | Qpqh | $238.5 Bil | |
NVS
| Novartis AG ADR | Jzqhnfx | Lyth | $209.5 Bil | |
RHHBY
| Roche Holding AG ADR | Tswwsqnl | Lcpx | $202.5 Bil | |
AMGN
| Amgen Inc | Khzntnsq | Ddf | $167.1 Bil | |
PFE
| Pfizer Inc | Qfbmrysd | Zdz | $163.3 Bil | |
SNY
| Sanofi SA ADR | Qhpfskkqh | Dpfw | $122.4 Bil |